# A Study to Learn How Safe the Study Drug BAY 2416964 (AhR Inhibitor) in Combination With the Treatment Pembrolizumab is, How This Combination Affects the Body, the Maximum Amount That Can be Given, How it Moves Into, Through and Out of the Body and Its Action Against Advanced Solid Cancers in Adults

> **NCT04999202** · PHASE1 · TERMINATED · sponsor: **Bayer** · enrollment: 47 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** BAY2416964
- **DRUG:** BAY2416964
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT04999202
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-08-30
- **Primary completion:** 2024-06-28
- **Final completion:** 2025-01-20
- **Target enrollment:** 47 (ACTUAL)
- **Why stopped:** Last patient ongoing on treatment ended the study on 20th January 2025. Hence, the end of study was reached as defined in the protocol.
- **Last updated:** 2025-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04999202

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04999202, "A Study to Learn How Safe the Study Drug BAY 2416964 (AhR Inhibitor) in Combination With the Treatment Pembrolizumab is, How This Combination Affects the Body, the Maximum Amount That Can be Given, How it Moves Into, Through and Out of the Body and Its Action Against Advanced Solid Cancers in Adults". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04999202. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*